Alcon Akcija

Alcon Debitori

Parādsaņemšanas no Alcon (ALC.SW) uz 2026. g. 4. aug. ir 1,94 B USD. Iepriekšējā gadā Parādsaņemšanas bija 1,74 B USD — izmaiņas 11,87 % (augstāks).

Debitori

1,94 BUSD

YoY

11,87%

Pēdējoreiz atjaunināts:

Parādsaņemšanas no Alcon ir 2026 1,94 B USD. Parādsaņemšanas no Alcon bija 2025 1,74 B USD. Tas samazinās par 11,87% augstāks salīdzinājumā ar iepriekšējo gadu.
Access this data via the Eulerpool API

Alcon Akciju analīze

Ko dara Alcon? Alcon AG is a leading company in ophthalmology with more than 70 years of experience in this industry. The company was founded in 1945 by Robert Alexander and William Conner and has its headquarters in Geneva, Switzerland. Alcon AG has been part of the Novartis Group since 2019 and is a leader in the production of ophthalmic products. The business model of Alcon AG is based on the manufacturing and sale of ophthalmic products. The company offers medical products such as contact lenses, surgical instruments, eye drops, and intraocular lenses. Alcon AG specializes in the development of products that can be used for various eye diseases. The company provides a wide range of products that can be used by ophthalmologists and opticians. The various divisions of Alcon AG include eye care products, surgical products, and diagnostic products. Eye care products, such as contact lenses, offer consumers a safe and easy way to correct their vision. Surgical products include a wide range of instruments used in eye surgeries. Diagnostic products help identify eye diseases and support treatment. Alcon AG specializes in the development of products for the treatment of eye diseases. These include conditions such as cataracts, glaucoma, and age-related macular degeneration. The company offers various products that can be used for these conditions, such as eye drops to reduce elevated eye pressure in glaucoma. It has also developed a wide range of products for refractive correction, allowing people to improve their vision. Alcon AG works closely with leading ophthalmologists and opticians to optimize its product development. This close collaboration ensures that Alcon AG's products meet the needs of patients and provide them with high safety and effectiveness. With its innovative products and technologies, Alcon AG aims to improve the quality of life for patients and provide them with optimal care and treatment. Overall, Alcon AG is a leading company in ophthalmology, offering its customers a wide range of innovative and high-quality products. From diagnosis to care to surgical interventions, Alcon AG's product range covers all areas of ophthalmology. The company is known for its research and development and is constantly working towards advancing ophthalmology. Through its continuous innovation and customer orientation, Alcon AG has established a strong position in the healthcare industry and will continue to introduce new products and technologies in the future. Alcon ir viens no populārākajiem uzņēmumiem Eulerpool.

Bieži uzdotie jautājumi par Alcon akciju

Alcon Parādsaņemšanas 2026. gadā ir 1,94 B USD.

Parādsaņemšanas no Alcon mainījās no 1,74 B USD uz 1,94 B USD, kas atspoguļo 11,87 % izmaiņas. Vērtība ir augstāks nekā iepriekšējā gadā.

Vietnē Eulerpool varat atrast pilnīgu Parādsaņemšanas Alcon vēsturisko attīstību kopš 2006. gada — ar gada vērtībām, grafikiem un detalizētu analīzi.

Debitoru parādi atspoguļo naudu, kas klientiem parādā uzņēmumam par piegādātajām precēm vai pakalpojumiem. Lieli debitoru parādi salīdzinājumā ar ieņēmumiem var norādīt uz iekasēšanas problēmām.

Rādītāji ietekmē akciju vērtējumu, signalizējot par peļņas kvalitāti, finansiālo veselību un izaugsmes trajektoriju. Spēcīgi rādītāji parasti noved pie augstākiem vērtējumiem.

Access this data via the Eulerpool API

Bilance — Alcon

Visas kategorijas